Novo Nordisk A/S
I · AI Analysis
The brief
Novo Nordisk develops and sells injectable and oral drugs primarily for diabetes and obesity, operating through two segments: Obesity and Diabetes Care (which includes cardiovascular treatments) and Rare Disease (covering blood disorders and hormone therapies) [Yahoo Finance]. The company also makes insulin delivery devices like smart pens and dose-tracking apps [Yahoo Finance]. Founded in 1923 and headquartered in Denmark, Novo Nordisk employs 67,900 people and sells its products globally across Europe, North America, Asia, and emerging markets [Yahoo Finance].
Novo Nordisk is a Danish pharmaceutical giant that makes diabetes and obesity drugs, most notably Wegovy and Ozempic (both forms of semaglutide) [Yahoo Finance]. The company is riding a massive wave of demand for GLP-1 weight-loss treatments, with recent trial data showing Wegovy works effectively in pill form and treats liver disease affecting one in three people with obesity [Yahoo Finance]. Despite strong financials and positive clinical momentum, the stock trades at a low 10.4x P/E ratio, which some analysts view as undervalued [Yahoo Finance].
Novo Nordisk is financially robust with exceptional margins, strong cash generation, and minimal debt burden [Yahoo Finance].
Sentinellis health
8.9/10
Financially healthy
Market capitalisation
$196.2B
Revenue (TTM)
DKK 309.1B
Explainers
How we read these numbers
Plain-English guides · no account needed
ROIC vs WACC Explained: How to Tell If a Company Actually Creates Value
What ROIC and WACC are, how to compute both, and why the spread between them is the single most important number in fundamental investing.
ReadPiotroski F-Score Explained: A 9-Point Financial Health Check (with a Live Apple Example)
What the Piotroski F-Score is, how to calculate all 9 criteria, and how to read the result. Plain English, with a real Apple walkthrough.
ReadAltman Z-Score Explained: Predicting Bankruptcy in 5 Minutes (with Real Examples)
What the Altman Z-Score is, the exact formula, how to read the result, and which version to use for manufacturers vs tech vs private companies.
ReadII · Recent news
What moved
6 stories · ranked by relevance
- Macro2026-05-20
How New Wegovy Obesity Trial Data At Novo Nordisk (CPSE:NOVO B) Has Changed Its Investment Story
Yahoo Finance
- Macro2026-05-18
3 Deeply Undervalued Stocks You Can Buy for Less Than $100 Right Now
Yahoo Finance
- Macro2026-05-19
Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide
Yahoo Finance
- Macro2026-05-19
Novo Nordisk Expands Parkinson's Bet With AI Partner And Upside Potential
Simply Wall St
- Macro2026-05-18
Novo Nordisk A/S - share repurchase programme
Yahoo Finance
- Macro2026-05-18
Novo Nordisk Eyes Global Push for Wegovy Pill
GuruFocus
Premium · Free with any account
Novo Nordisk faces intense competition from Eli Lilly and other players developing GLP-1 drugs, with pressure mounting as rival therapies gain market share and compounding pharmacies produce cheaper alternatives [Yahoo Finance].
Risks
4
Opportunities
7
Red flags
2
Leadership
10
12 more findings in the full report — free with any account.
Unlock the full Novo Nordisk A/S analysis
Create a free account to access the complete AI-generated report with inline citations.
- 4 risks, 7 opportunities and 2 red flags — each with its source
- 100+ financial metrics with charts and benchmarks
- Full news summaries with source links
- Executive team and compensation details
- PDF export for offline use
III · Related
You might also read
Same sector · Healthcare — or comparable health
Want this for your watchlist?